Report cover image

Bio/Pharmaceutical Outsourcing Report, April 2025

Publisher GlobalData
Published Apr 30, 2025
Length 30 Pages
SKU # GBDT20043799

Description

Bio/Pharmaceutical Outsourcing Report, April 2025

Summary

The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.

Scope

This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from GlobalData's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for -
  • CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.
  • Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.
  • Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.
Reasons to Buy
  • Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.
  • Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.
  • Learn about the past quarter’s M&A and financing deals in the manufacturing space.
  • Identify the latest contract service agreements.
  • Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.
  • Stay ahead of disruption with updates on supply chain obstacles and new regulations.

Table of Contents

30 Pages
    • Trump's first 100 days tout US-bound pharma investments amid tariff worries
    • Novartis to build $23B US sites for 100% domestic manufacturing
    • Biosimilar approvals surge to record high, a key opportunity for biologic CMOs
    • Data and relationships can mitigate clinical supply chain risk and cost
    • Europe proposes Critical Medicines Act to boost manufacturing and "Buy EU"
    • Contract service agreements
    • Contract manufacturing - opportunities and threats
    • Quarterly mergers, acquisitions, and financing - Q2 2025
    • Fiugre 5: The contract manufacturing value chain
    • Compounding
    • API chemical
    • API biologics - protein and peptide
    • API biologics - cell, gene, vaccine, and virus
    • Commercial dose manufacturing and packaging
    • Clinical dose manufacturing and packaging
    • Analytical services
  • About GlobalData
  • About the Authors
  • Contact Us

Search Inside Report

How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.